Rezolute (NASDAQ:RZLT) CFO Buys $70,800.00 in Stock

Rezolute, Inc. (NASDAQ:RZLT) CFO Daron Evans bought 40,000 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The shares were purchased at an average price of $1.77 per share, for a total transaction of $70,800.00. Following the completion of the purchase, the chief financial officer directly owned 415,900 shares of the company’s stock, valued at approximately $736,143. This trade represents a 10.64% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Daron Evans also recently made the following trade(s):

• On Monday, December 15th, Daron Evans purchased 5,000 shares of Rezolute stock. The stock was acquired at an average price of $1.79 per share, for a total transaction of $8,950.00.

Rezolute Trading Down 9.4%

Shares of Rezolute stock traded down $0.17 on Monday, hitting $1.63. The stock had a trading volume of 13,380,965 shares, compared to its average volume of 9,712,468. The stock has a market cap of $151.15 million, a price-to-earnings ratio of -1.75 and a beta of 0.21. Rezolute, Inc. has a 52-week low of $1.07 and a 52-week high of $11.46. The company’s 50 day moving average price is $9.00 and its 200 day moving average price is $7.17.

Rezolute (NASDAQ:RZLT) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.09. Analysts predict that Rezolute, Inc. will post -0.93 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Wall Street Zen lowered Rezolute from a “hold” rating to a “sell” rating in a report on Saturday. Craig Hallum downgraded Rezolute from a “buy” rating to a “hold” rating and set a $2.00 target price on the stock. in a research note on Thursday. Jefferies Financial Group restated a “buy” rating and set a $20.00 price target on shares of Rezolute in a research note on Friday, December 5th. BTIG Research reiterated a “buy” rating and issued a $5.00 price objective on shares of Rezolute in a research report on Thursday. Finally, Guggenheim dropped their price objective on shares of Rezolute from $15.00 to $6.00 and set a “buy” rating on the stock in a research note on Friday. Six investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Rezolute presently has an average rating of “Hold” and an average target price of $9.78.

Institutional Investors Weigh In On Rezolute

Several institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets acquired a new stake in shares of Rezolute in the 2nd quarter worth approximately $25,000. Ameritas Investment Partners Inc. acquired a new position in Rezolute in the 2nd quarter valued at about $30,000. Legal & General Group Plc acquired a new stake in shares of Rezolute during the 2nd quarter worth about $32,000. Raymond James Financial Inc. purchased a new stake in shares of Rezolute during the second quarter worth about $46,000. Finally, Paloma Partners Management Co purchased a new position in shares of Rezolute during the 1st quarter worth $48,000. 82.97% of the stock is currently owned by hedge funds and other institutional investors.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.